Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Debt (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Debt for 14 consecutive years, with $287.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Debt changed N/A to $287.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $287.6 million, a N/A change, with the full-year FY2025 number at $287.6 million, changed N/A from a year prior.
  • Total Debt was $287.6 million for Q4 2025 at Cytokinetics, up from $176.0 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $287.6 million in Q4 2025 to a low of $46.5 million in Q1 2021.
  • A 5-year average of $89.9 million and a median of $63.5 million in 2022 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: dropped 9.86% in 2023, then soared 73.31% in 2024.
  • Cytokinetics' Total Debt stood at $47.4 million in 2021, then skyrocketed by 36.74% to $64.8 million in 2022, then dropped by 9.86% to $58.4 million in 2023, then surged by 80.73% to $105.5 million in 2024, then skyrocketed by 172.53% to $287.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Total Debt are $287.6 million (Q4 2025), $176.0 million (Q3 2025), and $176.7 million (Q2 2025).